Pseudomonas Aeruginosa

News Pseudomonas Aeruginosa

• Exome sequencing of health condition extremes can reveal susceptibility genes

  Comparing the DNA from patients at the best and worst extremes of a health condition can reveal genes for resistance and susceptibly. This approach discovered rare variations in the DCTN4 gene among cystic fibrosis patients most prone to early, chronic airway infections.The DCTN4 gene codes for dyna more

• Intercell starts a pivotal Phase II/III efficacy study with its Pseudomonas aeruginosa vaccine candidate

  Intercell AG announced the start of a pivotal Phase II/III efficacy trial of its investigational Pseudomonas aeruginosa vaccine. The trial follows an exploratory Phase II study in which lower all-cause mortality rates were observed in the vaccine groups as compared to the control group. The Phase II more

• Intercell receives positive scientific advice from EMA for Pseudomonas vaccine Phase II/III-study

  Intercell AG announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the planned Phase II/III efficacy trial of its investigational Pseudomonas aeruginosa vaccine. The company obtained confirmation for the proposed key elements of the study design more

White papers Pseudomonas Aeruginosa

• Enzyme Kinetic Measurements for a Combinatorial Library of Inhibitors of Pseudomonas Elastase
  

  Pseudomonas elastase (LasB) is a key drug target in various chronic and intractable infections. A library of 160 potential, in-house synthesised, elastase inhibitors were screened using a fluorescence assay with the internally quenched substrate Abz-Ala-Gly-Leu-Ala-Nba. Enzymatic kinetic measurements were done on a FLUOstar OPTIMA and Km and Vmax values were calculated for each inhibitor using the MARS Data Analysis software more

Publications Pseudomonas Aeruginosa

• A deletion in the wapB promoter in many serotypes of P. aeruginosa accounts for the lack of a terminal glucose residue in the core oligosaccharide and resistance to killing by ...

  Summary Pseudomonas aeruginosa is an opportunistic human pathogen producing a variety of virulence factors. One of them is lipopolysaccharide, consisting of endotoxic lipid A and long‐chain O‐antigen polysaccharide, which are connected together through a short linker region, called core oligosac more

• The P. aeruginosa Heme Binding Protein PhuS Is a Heme Oxygenase Titratable Regulator of Heme Uptake

  The Pseudomonas aeruginosa heme utilization (Phu) system encodes several proteins involved in the acquisition of heme as an iron source. Once internalized, heme is degraded by the iron-regulated heme oxygenase, HemO to biliverdin (BV) IXδ and β. In vitro studies have shown holo-PhuS transfers heme t more

• The Gac/Rsm and cyclic‐di‐GMP signaling networks coordinately regulate iron uptake in Pseudomonas aeruginosa

  Abstract Pseudomonas aeruginosa is a versatile bacterial pathogen capable of occupying diverse ecological niches. To cope with iron limitation, P. aeruginosa secretes two siderophores, pyoverdine and pyochelin, whose ability to deliver iron to the cell is crucial for biofilm formation and pathog more

Market studies Pseudomonas Aeruginosa

• Pseudomonas Aeruginosa Infections – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2012', provides an overview of the Pseudomonas Aeruginosa Infections therapeutic pipeline. This report provides information on the therapeutic development for Pseudomonas Aeruginosa Infections, complete more

Websites Pseudomonas Aeruginosa